{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:46:29Z","timestamp":1794264389336,"version":"4.9.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:00:00Z","timestamp":1657324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:00:00Z","timestamp":1657324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["GSK (Study 115970)"],"award-info":[{"award-number":["GSK (Study 115970)"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Miridesap depletes circulating serum amyloid P (SAP) and dezamizumab (anti-SAP monoclonal antibody) targets SAP on amyloid deposits, triggering amyloid removal. In a phase 1, first-in-human study (FIHS), progressive amyloid removal was observed in some patients after\u2009\u2264\u20093 cycles of miridesap\/dezamizumab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This observational, non-interventional study in patients who received miridesap\/dezamizumab during the FIHS (planned follow-up: 5\u00a0years) evaluated response to treatment based on routine assessments of disease status and key organ function. In a post hoc analysis, patients responding to treatment in the FIHS during follow-up were identified as responders and further categorized as sustained or declining responders.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the FIHS, 17\/23 patients were treatment responders. Of these patients, seven (immunoglobulin light chain [AL], n\u2009=\u20096; serum amyloid A, n\u2009=\u20091) were considered sustained responders and ten (fibrinogen-a alpha chain [AFib], n\u2009=\u20095; AL, n\u2009=\u20094; apolipoprotein A-I, n\u2009=\u20091) were considered declining responders. We primarily present responder patient-level data for functional, cardiac, laboratory and imaging assessments conducted during the follow-up period, with non-responder data presented as supplementary.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>No further development of miridesap\/dezamizumab is planned in amyloidosis. However, long-term follow-up of these patients may provide insight into whether active removal of amyloid deposits has an impact on disease progression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>\n                           <jats:italic>Trial registration<\/jats:italic>\n                        <\/jats:title>\n                <jats:p>ClinicalTrials.gov, NCT01777243. Registered 28 January 2013, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01777243\">https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01777243<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02405-7","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T19:32:36Z","timestamp":1657395156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study"],"prefix":"10.1186","volume":"17","author":[{"given":"Duncan","family":"Richards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Millns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Cookson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0791-5580","authenticated-orcid":false,"given":"Mary Ann","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,9]]},"reference":[{"key":"2405_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/13506129.2016.1257986","volume":"23","author":"JD Sipe","year":"2016","unstructured":"Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23:209\u201313.","journal-title":"Amyloid"},{"key":"2405_CR2","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641\u201354.","journal-title":"Lancet"},{"key":"2405_CR3","unstructured":"(ISA) ISoA. Amyloidosis the disease. https:\/\/www.isaamyloidosis.org\/about\/amyloidosis-the-disease.php."},{"key":"2405_CR4","doi-asserted-by":"publisher","first-page":"12200","DOI":"10.1038\/s41598-019-48513-6","volume":"9","author":"D Kim","year":"2019","unstructured":"Kim D, Lee GY, Choi JO, Kim K, Kim SJ, Ju ES, et al. Prognostic values of novel biomarkers in patients with AL amyloidosis. Sci Rep. 2019;9:12200.","journal-title":"Sci Rep"},{"key":"2405_CR5","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541\u20139.","journal-title":"J Clin Oncol"},{"key":"2405_CR6","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129:2111\u20139.","journal-title":"Blood"},{"key":"2405_CR7","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","volume":"32","author":"I Lousada","year":"2015","unstructured":"Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther. 2015;32:920\u20138.","journal-title":"Adv Ther"},{"key":"2405_CR8","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40265-019-01129-6","volume":"79","author":"YN Lamb","year":"2019","unstructured":"Lamb YN, Deeks ED. Tafamidis: a review in transthyretin amyloidosis with polyneuropathy. Drugs. 2019;79:863\u201374.","journal-title":"Drugs"},{"key":"2405_CR9","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","volume":"78","author":"SJ Keam","year":"2018","unstructured":"Keam SJ. Inotersen: first global approval. Drugs. 2018;78:1371\u20136.","journal-title":"Drugs"},{"key":"2405_CR10","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy SM. Patisiran: first global approval. Drugs. 2018;78:1625\u201331.","journal-title":"Drugs"},{"key":"2405_CR11","doi-asserted-by":"publisher","first-page":"21038","DOI":"10.1074\/jbc.M314008200","volume":"279","author":"CA MacRaild","year":"2004","unstructured":"MacRaild CA, Stewart CR, Mok YF, Gunzburg MJ, Perugini MA, Lawrence LJ, et al. Non-fibrillar components of amyloid deposits mediate the self-association and tangling of amyloid fibrils. J Biol Chem. 2004;279:21038\u201345.","journal-title":"J Biol Chem"},{"key":"2405_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/417254a","volume":"417","author":"MB Pepys","year":"2002","unstructured":"Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 2002;417:254\u20139.","journal-title":"Nature"},{"key":"2405_CR13","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1002\/psp4.15","volume":"4","author":"T Sahota","year":"2015","unstructured":"Sahota T, Berges A, Barton S, Cookson L, Zamuner S, Richards D. Target mediated drug disposition model of CPHPC in patients with systemic amyloidosis. CPT Pharmacomet Syst Pharmacol. 2015;4:e15.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"2405_CR14","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/j.1365-2141.2009.08036.x","volume":"148","author":"JD Gillmore","year":"2010","unstructured":"Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol. 2010;148:760\u20137.","journal-title":"Br J Haematol"},{"key":"2405_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature09494","volume":"468","author":"K Bodin","year":"2010","unstructured":"Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010;468:93\u20137.","journal-title":"Nature"},{"key":"2405_CR16","doi-asserted-by":"publisher","first-page":"eaan3128","DOI":"10.1126\/scitranslmed.aan3128","volume":"10","author":"DB Richards","year":"2018","unstructured":"Richards DB, Cookson LM, Barton SV, Liefaard L, Lane T, Hutt DF, et al. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Sci Transl Med. 2018;10:eaan3128.","journal-title":"Sci Transl Med."},{"key":"2405_CR17","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","volume":"373","author":"DB Richards","year":"2015","unstructured":"Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med. 2015;373:1106\u201314.","journal-title":"N Engl J Med"},{"key":"2405_CR18","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJM199008233230803","volume":"323","author":"PN Hawkins","year":"1990","unstructured":"Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med. 1990;323:508\u201313.","journal-title":"N Engl J Med"},{"key":"2405_CR19","first-page":"57","volume":"17","author":"DF Hutt","year":"2010","unstructured":"Hutt DF, Lane T, Gillmore JD, Lachmann HJ, Gibbs SDJ, Sattianayagam PT, et al. Role of dual modality I123 serum amyloid P component SPECT-CT imaging in amyloidosis. Amyloid. 2010;17:57.","journal-title":"Amyloid"},{"key":"2405_CR20","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJMc1917321","volume":"382","author":"S Ravichandran","year":"2020","unstructured":"Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and survival trends in amyloidosis, 1987\u20132019. N Engl J Med. 2020;382:1567\u20138.","journal-title":"N Engl J Med"},{"key":"2405_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","volume":"11","author":"A Staron","year":"2021","unstructured":"Staron A, Zheng L, Doros G, Connors LH, Mendelson LM, Joshi T, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021;11:139.","journal-title":"Blood Cancer J"},{"key":"2405_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","volume":"20","author":"A Casta\u00f1o","year":"2015","unstructured":"Casta\u00f1o A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015;20:163\u201378.","journal-title":"Heart Fail Rev"},{"key":"2405_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jacc.2016.04.035","volume":"68","author":"AV Kristen","year":"2016","unstructured":"Kristen AV, Brokbals E, aus dem Siepen F, Bauer R, Hein S, Aurich M, et al. Cardiac amyloid load: a prognostic and predictive biomarker in patients with light-chain amyloidosis. J Am Coll Cardiol. 2016;68:13\u201324.","journal-title":"J Am Coll Cardiol"},{"key":"2405_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/01.md.0000091183.93122.c7","volume":"82","author":"MA Park","year":"2003","unstructured":"Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore). 2003;82:291\u20138.","journal-title":"Medicine (Baltimore)"},{"key":"2405_CR25","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","volume":"126","author":"G Palladini","year":"2015","unstructured":"Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126:612\u20135.","journal-title":"Blood"},{"key":"2405_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12872-021-02407-6","volume":"22","author":"A Wechalekar","year":"2022","unstructured":"Wechalekar A, Antoni G, Al Azzam W, Bergstrom M, Biswas S, Chen C, et al. Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study. BMC Cardiovasc Disord. 2022;22:49.","journal-title":"BMC Cardiovasc Disord"},{"key":"2405_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/jep.12629","volume":"23","author":"RW Bohannon","year":"2017","unstructured":"Bohannon RW, Crouch R. Minimal clinically important difference for change in 6-minute walk test distance of adults with pathology: a systematic review. J Eval Clin Pract. 2017;23:377\u201381.","journal-title":"J Eval Clin Pract"},{"key":"2405_CR28","unstructured":"NCI. Common Terminology Criteria for Adverse Events (CTCAE). https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html."},{"key":"2405_CR29","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/leu.2012.100","volume":"26","author":"RL Comenzo","year":"2012","unstructured":"Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26:2317\u201325.","journal-title":"Leukemia"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02405-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02405-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02405-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T19:32:41Z","timestamp":1657395161000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02405-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,9]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2405"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02405-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,9]]},"assertion":[{"value":"8 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol, any amendments, the informed consent, and other information that required pre-approval were reviewed and approved by a single investigational ethics committee (Wales Research Ethics Committee, Cardiff, UK), in accordance with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice and applicable country-specific requirements. Written informed consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HM, LC and MAL are employees of and hold stocks\/shares in GSK. DR was an employee of GSK at the time of study conduct.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"259"}}